PUBLISHER: Allied Market Research | PRODUCT CODE: 1298241
PUBLISHER: Allied Market Research | PRODUCT CODE: 1298241
The Pain Patches Market valued for $4,803.70 million in 2021 and is estimated to reach $7,338.07 million by 2031, exhibiting a CAGR of 4.3% from 2022 to 2031.
Pain patches are a transdermal method of pain relief that involves the application of medication to the skin, where it is absorbed into the bloodstream through the skin. These patches are designed to provide continuous, controlled release of medication over a period of time, which can help manage pain effectively. They are typically used for chronic pain conditions that require ongoing treatment, such as arthritis, back pain, and neuropathic pain. The medication can be either an opioid, such as fentanyl or buprenorphine, or a non-opioid, such as lidocaine or diclofenac. They are available as over the counter (OTC) products while most of these are available through prescription only.
The driving factor for pain patch market are increase in geriatric population, rise in usage of pain patches and increase in prevalence of chronic pain cases. For instance, according to U.S. Pain Foundation 2022 report, every year 50 million people suffer from chronic pain. Thus, rise in prevalence of chronic pain cases is expected to drive the growth of the market. In addition, the geriatric population is majorly prone to suffer from joint pain, neuropathic pain and other chronic pain conditions. Thus, rise in geriatric population potentially drives the market growth.
Furthermore, increase in awareness associated with advance method for pain management and availability of OTC pain patches products such as methyl salicylate and nitroglycerin are predicted to boost the growth of the market. In addition, rise in advancement in patches technology is anticipated to boost the market growth. Furthermore, many key players have adopted key strategies such as collaboration, business expansion, or alliance to increase their market presence in the global pain patch market. For instance, in August 2022, Sorrento Therapeutics Inc., announced that, ZTlido (lidocaine topical system) will be added to one of the largest National Pharmacy Benefit Managers (PBMs) and a national health plan - thereby expanding coverage to 30 million lives. Thus, such business expansions are expected to drive the growth of the market.
However, factors such as availability of alternative treatment such as acupuncture, physical therapy, and chiropractic care are projected to restrain the growth of the pain patch market. In addition, stringent government regulations associated with manufacturing and marketing of opioid-containing pain patches is expected to hamper the growth of the market.
The pain patch market is segmented into therapeutic class, type, distribution channel, and region. On the basis of therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioid segment is further categorized into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, lidocaine and others. The opioid segment is further categorized into buprenorphine and fentanyl. On the basis of type, the market is bifurcated into prescription medicines and OTC medicines. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major key players that operate in the global pain patch market are: NEXGEL Advanced Hydrogel Solutions, Viatris Inc., Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sorrento Therapeutics Inc., Hisamitsu Pharmaceutical Co.,Inc., Endo International plc., Purdue Pharma L.P., Amneal Pharmaceuticals LLC, and Grunenthal .